TG Therapeutics to Participate in the B. Riley Securities Fall 2021 Growth Biotech Best Ideas Virtual Series
TG Therapeutics, Inc. (NASDAQ: TGTX) announced a fireside chat with CEO Michael S. Weiss scheduled for November 11, 2021, at 12:00 PM ET, during the B. Riley Securities’ Fall 2021 Growth Biotech Best Ideas Virtual Series. The event will be accessible via a live webcast on the company's website, with a replay available post-event. TG Therapeutics focuses on innovative treatments for B-cell malignancies and autoimmune diseases, including UKONIQ®, which has received accelerated FDA approval.
- None.
- None.
Fireside chat scheduled for 12:00 PM ET on Thursday November 11, 2021
NEW YORK, Nov. 09, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in a fireside chat during the B. Riley Securities’ Fall 2021 Growth Biotech Best Ideas Virtual Series, taking place on Thursday November 11, 2021, at 12:00 PM ET.
A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company’s website at http://ir.tgtherapeutics.com/events. A replay of the webcast will be available on TG’s website following the event.
ABOUT TG THERAPEUTICS, INC.
TG Therapeutics is a fully-integrated, commercial stage biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. In addition to an active research pipeline including five investigational medicines across these therapeutic areas, TG has received accelerated approval from the U.S. FDA for UKONIQ® (umbralisib), for the treatment of adult patients with relapsed/refractory marginal zone lymphoma who have received at least one prior anti-CD20-based regimen and relapsed/refractory follicular lymphoma who have received at least three prior lines of systemic therapies. Currently, the Company has three programs in Phase 3 development for the treatment of patients with relapsing forms of multiple sclerosis (RMS) and patients with chronic lymphocytic leukemia (CLL) and several investigational medicines in Phase 1 clinical development. For more information, visit www.tgtherapeutics.com, and follow us on Twitter @TGTherapeutics and Linkedin.
UKONIQ® is a registered trademark of TG Therapeutics, Inc.
| CONTACT: | |
| Investor Relations | |
| Email: ir@tgtxinc.com | |
| Telephone: 1.877.575.TGTX (8489), Option 4 | |
| Media Relations: | |
| Email: media@tgtxinc.com | |
| Telephone: 1.877.575.TGTX (8489), Option 6 | |
FAQ
What is the date and time of the TG Therapeutics fireside chat?
Who will be participating in the TG Therapeutics fireside chat?
Where can I watch the TG Therapeutics fireside chat?
What key product is mentioned in the TG Therapeutics press release?
What are TG Therapeutics' main research focuses?
